logo.png
Orphazyme presents 36-month data supporting durable response to arimoclomol during Parseghian Scientific Conference for NPC Research
June 28, 2021 02:00 ET | ORPHAZYME A/S
Orphazyme A/SCompany announcement        No. 21/2021Company Registration No. 32266355 Copenhagen – June 28, 2021 – Orphazyme A/S (ORPHA.CO; ORPH), a late-stage biopharmaceutical company, today...
logo.png
Orphazyme announces restructuring to focus resources on supporting a path forward for arimoclomol in NPC
June 28, 2021 00:00 ET | ORPHAZYME A/S
Orphazyme A/SCompany announcement        No. 20/2021Inside informationCompany Registration No. 32266355 -Significant headcount reduction of global workforce to free resources- -Changes to the...
logo.png
Major shareholder announcement
June 24, 2021 07:31 ET | ORPHAZYME A/S
Orphazyme A/SCompany announcement        No. 19/2021Company Registration No. 32266355 Copenhagen, Denmark, June 24, 2021 – Orphazyme A/S (ORPHA.CO; ORPH) (“the Company”), a late-stage...
logo.png
Major shareholder announcement
June 23, 2021 05:43 ET | ORPHAZYME A/S
Orphazyme A/SCompany announcement        No. 18/2021Company Registration No. 32266355 Copenhagen, Denmark, June 23, 2021 – Orphazyme A/S (ORPHA.CO; ORPH) (“the Company”), a late-stage...
logo.png
Orphazyme provides regulatory update from FDA on arimoclomol for Niemann-Pick disease type C
June 18, 2021 01:00 ET | ORPHAZYME A/S
Orphazyme A/SCompany announcement        No. 16/2021Inside informationCompany Registration No. 32266355   Copenhagen – June 18, 2021 – Orphazyme A/S (ORPHA.CO; ORPH), a late-stage...
logo.png
Major shareholder announcement
June 15, 2021 11:05 ET | ORPHAZYME A/S
Orphazyme A/SCompany announcement        No. 16/2021Company Registration No. 32266355 Copenhagen, Denmark, June 15, 2021 – Orphazyme A/S (ORPHA.CO; ORPH) (“the Company”), a late-stage...
logo.png
Orphazyme addresses recent trading activity
June 11, 2021 03:42 ET | ORPHAZYME A/S
Orphazyme A/SCompany announcement        No. 15/2021Company Registration No. 32266355 Copenhagen – June 11, 2021 - Orphazyme A/S (ORPHA.CO; ORPH), a late-stage biopharmaceutical company pioneering...
logo.png
Orphazyme announces topline data from pivotal trial of arimoclomol in Amyotrophic Lateral Sclerosis (ALS)
May 07, 2021 01:00 ET | ORPHAZYME A/S
Orphazyme A/SCompany announcementNo. 14/2021Inside informationCompany Registration No. 32266355 Pivotal trial did not meet primary and secondary endpoints evaluating impact on function and...
logo.png
Orphazyme to present at upcoming investor conferences
April 27, 2021 16:05 ET | ORPHAZYME A/S
Orphazyme A/SInvestor news        No. 05/2021Company Registration No. 32266355 Copenhagen, Denmark and Chicago, IL, USA, April 27, 2021 – Orphazyme A/S [ORPHA.CO (DK); ORPH (US)], a late-stage...
logo.png
New long-term share-based incentive program
April 22, 2021 00:34 ET | ORPHAZYME A/S
Orphazyme A/SCompany announcement        No. 13/2021Company Registration No. 32266355 Copenhagen, Denmark, April 22, 2021 – Orphazyme A/S [ORPHA.CO (DK); ORPH (US)], a late-stage biopharmaceutical...